Lycia Therapeutics, Inc. Chief Medical Officer and 10% owner Chin Hyok Lee reported direct holdings of options to buy 366,402 common shares at an exercise price of $2.44, expiring February 12, 2035, and 73,191 common shares at $3.70, expiring August 10, 2036. As of October 22, 2026, the first award had vested as to 1/4, with an additional 1/48 of the total award to vest monthly; the second had vested as to 1/48, with an additional 1/48 to vest monthly. Both schedules are subject to Lee's service to Lycia on each vesting date.
Lycia Therapeutics, Inc. reports that Chief Financial Officer Amy Bachrodt, also identified as a 10% owner, directly holds stock options covering 399,746 common shares. The options have a $3.70 exercise price and expire August 10, 2036. One-quarter of the award vests June 2, 2027, with an additional 1/48 vesting monthly thereafter, subject to her service on each vesting date.
Lycia Therapeutics, Inc. (LYCA) lists President and CEO, director, and ten percent owner Aetna Wun Trombley’s direct options covering 471,252 shares at $1.63, fully vested, expiring October 19, 2031; 665,380 at $2.44, expiring June 27, 2034; 55,448 at $2.35, expiring February 9, 2036; and 443,586 at $3.70, expiring August 10, 2036. The latter three awards vest monthly, subject to her providing service on each vesting date. The Trombley Family Trust, of which she and her spouse are trustees, holds 415,255 common shares.
Lycia Therapeutics, Inc. is offering 14,700,000 shares of common stock in a proposed IPO at an expected $16.00–$18.00 per share; the offering is contingent on Nasdaq Global Select Market listing approval under LYCA. At the assumed $17.00 midpoint, estimated net proceeds are approximately $227.8 million, or approximately $262.7 million if underwriters exercise in full their 30-day option for up to 2,205,000 additional shares. Proceeds are intended for clinical development of its IgE and Graves’ disease programs, other research and development, working capital and general corporate purposes.
Preliminary Phase 1 data for LCA-0061 showed a mean maximum IgE reduction of 96% from baseline after a single 70 mg subcutaneous dose in healthy atopic participants; a majority remained more than 95% reduced from baseline 28 days after dosing, with no safety signals or dose-limiting toxicities observed. LCA-0321 is in Phase 1 for Graves’ disease, with initial data expected in 2027. LCA-0062 is in IND-enabling activities, with a Phase 1 trial planned if regulatory clearance is received and initial data expected in the second half of 2027. Estimated cash, cash equivalents and marketable securities were approximately $138.2 million as of September 30, 2026; this estimate is preliminary and unaudited. Lycia reported net losses of $36.5 million in 2025 and $19.2 million in the six months ended June 30, 2026, and has no products approved for commercial sale or product sales revenue.